The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 27, 2017
Filed:
Nov. 14, 2013
Applicant:
Elc Management, Llc, Melville, NY (US);
Inventors:
Donald F. Collins, Plainview, NY (US);
Daniel H. Maes, Huntington, NY (US);
Neelam Muizzuddin, Bethpage, NY (US);
Assignee:
ELC Management LLC, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/19 (2006.01); A61K 36/752 (2006.01); A61K 36/02 (2006.01); A61K 31/522 (2006.01); A61K 31/573 (2006.01); A61K 35/614 (2015.01); A61K 31/05 (2006.01); A61K 36/28 (2006.01); A61K 36/185 (2006.01); A61K 36/575 (2006.01); A61K 36/38 (2006.01); A61K 9/00 (2006.01); A61K 36/05 (2006.01); A61K 36/53 (2006.01); A61K 36/704 (2006.01); A61K 47/24 (2006.01); A61K 47/32 (2006.01); A61K 9/107 (2006.01); A61K 45/06 (2006.01); A61K 31/133 (2006.01);
U.S. Cl.
CPC ...
A61K 36/752 (2013.01); A61K 9/0014 (2013.01); A61K 9/107 (2013.01); A61K 31/05 (2013.01); A61K 31/133 (2013.01); A61K 31/19 (2013.01); A61K 31/522 (2013.01); A61K 31/573 (2013.01); A61K 35/614 (2013.01); A61K 36/02 (2013.01); A61K 36/05 (2013.01); A61K 36/185 (2013.01); A61K 36/28 (2013.01); A61K 36/38 (2013.01); A61K 36/53 (2013.01); A61K 36/575 (2013.01); A61K 36/704 (2013.01); A61K 45/06 (2013.01); A61K 47/24 (2013.01); A61K 47/32 (2013.01);
Abstract
A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.